Value-Based Diagnostics within Chronic Inflammatory Disease

Tuesday, September 28, 7 – 8:30 a.m.
Hyatt Regency, Regency Ballroom V
Supported by Thermo Fisher Scientific


The CDC ranks chronic inflammatory diseases as the greatest threat to human health, with prevalence rates expected to continually increase over the next 30 years. Diagnostics can play a virtual role in risk stratification, early identification, and management of these deadly diseases. Understanding the nuances of diagnostic testing that can lend value-based care is a necessary aspect to consider as health systems look to positively impact the associated economic burden of chronic inflammatory diseases at a population level.


Attendees will learn to:

  • Illustrate the health and economic burden of chronic inflammatory diseases
  • Highlight the connections between value-based diagnostics and population health management
  • Examine the potential impact of appropriate and innovative diagnostics and algorithms on the overall burden of chronic disease management


Veena Joy, MSc
U.S. Clinical Affairs Manager, Autoimmunity
Thermo Fisher Scientific
Portage, MI


Donna Wolk, JHA, PhD
Division Chief, Department of Molecular and Microbial Diagnostics
Geisinger Medical Center
Danville, PA